| 发明名称 | Robo1-Fc fusion protein and use thereof for treating tumours | ||
| 摘要 | The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient. | ||
| 申请公布号 | US9493529(B2) | 申请公布日期 | 2016.11.15 |
| 申请号 | US201113641012 | 申请日期 | 2011.04.08 |
| 申请人 | Sanofi | 发明人 | Blanche Francis;Cameron Beatrice;Dabdoubi Tarik;Dol-Gleizes Frederique;Fons Pierre;Prades Catherine;Herault Jean-Pascal |
| 分类号 | C07K14/475 | 主分类号 | C07K14/475 |
| 代理机构 | Lathrop & Gage LLP | 代理人 | Lathrop & Gage LLP ;Velema, Esq. James H. |
| 主权项 | 1. A homogeneous composition of Robo-Fc recombinant protein comprising the extracellular region of a Robo1 protein, a linker and an immunoglobulin Fc domain, wherein said extracellular region of the Robo1 protein consists of the Ig1 and Ig2 immunoglobulin domains corresponding to amino acids 22-220 of SEQ ID NO: 2, wherein the immunoglobulin Fc domain is from human immunoglobulin G4 and comprises S241P and L248E mutations (Kabat numbering), and wherein the lysine located in the C-terminal position is absent. | ||
| 地址 | Paris FR | ||